

November 30, 2016

Re: Completion of Investment in Bio-Life Marketing Sdn. Bhd. by Mega Lifesciences Public Company Limited (hereinafter the 'Company')

Attention: The President, The Stock Exchange of Thailand

With reference to the letter of the Company dated November 18, 2016.

The Board of Directors in its meeting number 05/2016 convened on September 15, 2016 has passed the resolution authorizing the management to pursue acquisition of 100% equity/ ordinary shares of Bio-Life Marketing Sdn. Bhd., Malaysia and accordingly a Share Sale Agreement was signed on November 18, 2016 for a consideration of Ringgit Malaysian Seventy five Million (75,000,000) or Thai Baht Six Hundred Five Million (Thb 605,000,000) arrived at by using exchange rate of Thai Baht 8.07/ Malaysia Ringgit 1. The shares were acquired on a cash free, debt free basis.

The transaction size was 8.1% based on the total consideration criteria as per letter dated Nov 18, 2016 and combined further with the Company's investment announced on September 16, 2016 the total investment in the last 6 months is 16.2% of the total assets based on the total consideration criteria.

The provisional consideration of Ringgit Malaysian Seventy Five Million (75,000,000) on a cash free, debt free basis has been adjusted to Ringgit Malaysia Seventy Seven Million Three Fifty seven Thousand Three Hundred and Thirty seven (77,357,337) on account of final working capital adjustment. The amount in Thai Baht is Six hundred Twenty One Thousand Three Eighty one thousand Three Hundred Thirty one (Thb 621,381,331) using actual exchange rate of Thai Baht 8.03/ Malaysia Ringgit 1 as compared to Thai Baht Six Hundred Five Million (605,000,000) announced earlier due to adjustments on account of working capital and difference between published and actual realized exchange rates.

Accordingly, the transaction size is 8.3% based on the total consideration criteria in accordance with the Notification of the Stock Exchange of Thailand regarding Disclosure of Information and Actions of a Listing Company on Acquisition or Disposition of Assets, 2004. Combined further with the Company's investment announced on September 16, 2016 the total investment in the last 6 months is 16.4% of the total assets based on the total consideration criteria. The transaction remains a Type 2 acquisition.

The transaction has been executed by the Company through Mega Lifesciences Sdn. Bhd. a subsidiary company in Malaysia.

Please be informed accordingly.

Yours Faithfully



(Vivek Dhawan)

Director and Chief Executive Officer



MEGA LIFESCIENCES Public Company Limited

384 Moo 4, Pattana 3 Road, Bangpoo Industrial Estate,
Soi 6, Preaksa, Muang Samutprakarn,
Samutprakarn 10280, Thailand

Telephone +66 (0)2 401 8686 Fax +66 (0)2 324 0451

info@megawecare.com

www.megawecare.com